On April 20, the peptide-drug-R&D project jointly delivered by CMIT-affiliated Advanced-Technology Institute, Tianjin Institute of Pharmaceutical Research and Professor Xuechen Li's team of HKU secured funding recommendation under Batch 3 of the RIC 1+ Programme. It validates the Group's scientific‑research cooperation with HKU and serves as a landmark outcome of joint innovation with Hong‑Kong universities.